Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

December 31, 1999

Study Completion Date

October 31, 2004

Conditions
Ovarian Cancer
Interventions
DRUG

Topotecan

Trial Locations (18)

10117

Clinic for Gynecology and Gyn. Oncology, Humboldt University, Berlin

17487

Gynecologic Clinic of the Ernst-Moritz-Arndt-University, Greifswald

24105

University Clinic Schleswig-Holstein, Campus Kiel, Clinic for gynecology and obstetrics, Kiel

30659

Gynecological Clinic of the Medical University, Hanover

37075

University Gynecologic Hospital, Göttingen

39108

Otto-von-Guericke University, University Gynecological Hospital, Magdeburg

40217

Gynecologic Hospital, Düsseldorf

40225

University Gynecologic Hospital, Düsseldorf

48149

Clinic for Gynecology, Münster

52074

Gynecologic Hospital of the Medical Facilities RWTH, Aachen

60596

University Gynecologic Hospital, Frankfurt

65199

Clinic for Gnyecology and gyn. Oncology HSK, Wiesbaden

72076

University Gynecologic Hospital, Tübingen

76137

St. Vincentius Gynecologic Hospital, Karlsruhe

81377

University Gynecologic Hospital Grosshadern, München

81675

"University Gynecologic Hospital rechts der Isar", München

89075

University Gynecological Hospital, Ulm

01307

University Clinic Carl Gustav Carus, Gynecological hospital, Dresden

All Listed Sponsors
lead

AGO Study Group

OTHER

NCT00102375 - Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer | Biotech Hunter | Biotech Hunter